• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie 4/2014
str. 32

Zastosowanie afliberceptu w leczeniu mokrej postaci zwyrodnienia plamki związanego z wiekiem w przypadku lekooporności na bewacyzumab i ranibizumab – doniesienie wstępne

Alfibercept in Wet AMD in Tachyphylaxis Against Bevacizumab and/or Ranibizumab – Preliminary Report

Piotr Fryczkowski, Agnieszka Siennicka, Agnieszka Nowosielska

Szpital Okulistyczny i Przychodnia Okulistyczna Retina w Warszawie
Kierownik: dr n. med. Piotr Fryczkowski

Summary: Aim of the study: comparison the aflibercept effect in cases of tachyphylaxis against bevacizumab and/or ranibizumab.
Material and Methods: 30 eyes of 28 patients (16 females, 12 males) age 63–90, mean 78. Previous therapy: 3 patients had photodynamic therapy, 14 – ranibizumab injections (mean 8.42), 15 – bevacizumab injections (mean 7.52). 6 patients (8 eyes) had injections of both formulations (ranibizumab and bevacizumab). Resistance to therapy was defined as no reaction based on subretinal fluid presence and/ or reduction of the area of membrane activity.
Results: In our study positive reaction was observed in 21 eyes, 9 eyes were stable with no signs of fluid limitation or improvement in visual function. Results are consistent with previous reports which establish positive reaction on pan-VEGF (ranibizumab, bevacizumab, aflibercept) drugs at 70% level.
Conclusion: The most important is that change in the therapy may be effective against specific VEGF isoforms characteristic in individual age-related macular degeneration process. As long as we haven’t have biomarkers specific to VEGF we should relay on empiric selection of the VEGF formulations.

Słowa kluczowe: aflibercept, bewacyzumab, ranibizumab, zwyrodnienie plamki związane z wiekiem (AMD), tachyfilaksja.

Keywords: aflibercept, bevacizumab, ranibizumab, age-related macular degeneration (AMD), tachyphilaxis.

powrót